viewTissue Regenix Group PLC

Tissue Regenix boss to take leave of absence to undergo medical treatment

Steve Couldwell will step aside in January in order to undergo treatment for an unspecified medical condition, although he should be back by March

steve couldwell
Chairman John Samuel will take over the reins in Couldwell’s absence

Steve Couldwell, the chief executive of regenerative medicines specialist Tissue Regenix Group PLC (LON:TRX), is taking a temporary leave of absence early next year in order to undergo medical treatment.

Couldwell will temporarily step aside in January and is expected to be out of action until March.

READ: TRX's CellRight subsidiary inks European distribution deal

In his absence, chairman John Samuel will become executive chairman, while chief financial officer Gareth Jones will take on the role of chief operating officer.

Samuel and Jones will hold those positions on an interim basis.

“Steve has done an excellent job of establishing a sound business strategy and delivering positive sales momentum,” said chairman Samuel.

“We are confident we will continue to execute against this strategy and on behalf of the Board and everyone at Tissue Regenix, I wish Steve a full and speedy recovery.”

As for current trading, a brief line at the end of the stock exchange announcement confirmed that the company remains on track to meet full-year expectations.

Quick facts: Tissue Regenix Group PLC

Price: 0.33 GBX

Market: AIM
Market Cap: £23.21 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Tissue Regenix Group PLC named herein, including the promotion by the Company of Tissue Regenix Group PLC in any Content on the Site, the...



Tissue Regenix "advancing on many fronts" says CEO after SurgiPure FDA clearance

Antony Odell, chief executive at Tissue Regenix (LON:TRX), talks to Proactive Investors about the US FDA clearance for SurgiPure XD, a skin graft for hernias derived from pig tissue. The group, which already has experience of commercialising products in the US, is planning a commercial...

on 03/09/2016

2 min read